Pracinostat Granted Breakthrough Therapy Designation for AML in Elderly Patients

Share this content:
The FDA granted Breakthrough Therapy Designation to pracinostat in combination with azacitidine for the treatment of acute myeloid leukemia.
The FDA granted Breakthrough Therapy Designation to pracinostat in combination with azacitidine for the treatment of acute myeloid leukemia.

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to pracinostat in combination with azacitidine for the treatment of patients with newly-diagnosed acute myeloid leukemia (AML) who are older than 75 years or unfit for intensive chemotherapy, according to a news release.1

The designation was granted because of results from a phase 2 study of pracinostat plus azacitidine in elderly patients who were not candidates for induction chemotherapy. Patients had a median overall survival of 19.1 months and a complete response rate of 42%.

The results were found to have compared favorably to findings from a phase 3 study of azacitidine, which showed a median overall survival of 10.4 months with azacitidine alone and a complete response rate of 19.5% in a similar patient population. Combination pracinostat and azacitidine was found to be generally well-tolerated with no unexpected toxicities.

RELATED: Vyxeos Improves Survival in Patients With High-risk AML

MEI Pharma reached an agreement with the FDA on a proposed phase 3 study design.

“This designation speaks to both the serious unmet need for AML patients unfit to receive intensive chemotherapy and the promise of pracinostat to address this need,” said Daniel Gold, PhD, president and chief executive officer of MEI Pharma.

Reference

  1. MEI Pharma's pracinostat receives breakthrough therapy designation from FDA for treatment in combination with azacitidine of patients with newly diagnosed acute myeloid leukemia unfit for intensive chemotherapy. PRNewswire. http://www.prnewswire.com/news-releases/mei-pharmas-pracinostat-receives-breakthrough-therapy-designation-from-fda-for-treatment-in-combination-with-azacitidine-of-patients-with-newly-diagnosed-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy-300306674.html. Updated August 1, 2016. Accessed August 1, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs